Harpoon has a portfolio of innovative T-cell engagers using the company’s proprietary TriTAC and ProTriRAC platforms to harness and activate a patient’s immune system to eliminate malign cells. During 2023, Harpoon shares climbed by 41% and surged by almost 112% on Monday. Analysts believe Merck is exploring new avenues of growth as its current top-selling…
Read more
This bullish stock performance follows on the heels of a key study that found Wegovy, the Novo Nordisk weight loss drug, reduces cardiac risks and related mortalities in obese people. Those involved in the study took the highest dose of the drug and consequently experienced a drop in blood sugar and inflammation, two of the…
Read more
Bayer’s chief executive officer, Bill Anderson, said: We are looking closely at our structural options. We have an expert team – including external financial advisors – evaluating them. They’re reviewing market conditions, what structural changes would mean for our value creation, one-time costs and dis-synergies, cash flows and leverage ratios, tax leakage, and other criteria.…
Read more